Arrowhead Teeing Up Drug Trials - Los Angeles Business Journal
Arrowhead Pharmaceuticals is preparing two RNAi-based drugs for obesity and metabolic diseases, aiming to start clinical trials early next year.
Reference News
Arrowhead Pharmaceuticals filed for regulatory clearance to initiate a Phase 1/2a clinical trial of ARO-INHBE, an RNAi therapeutic for obesity, and plans to file for ARO-ALK7 by 2024. Preclinical studies suggest ARO-INHBE reduces body weight and fat mass while preserving lean muscle mass.
Arrowhead Pharmaceuticals has applied to launch a Phase I/IIa trial of ARO-INHBE, an RNAi therapy for obesity, in New Zealand. The study will assess safety, tolerability, pharmacokinetics, and pharmacodynamics in up to 78 obese adult subjects, both diabetic and non-diabetic. The trial will evaluate ARO-INHBE as a standalone treatment and in combination with tirzepatide, a medication for type 2 diabetes and weight control. ARO-INHBE targets the INHBE gene to reduce Activin E secretion, which regulates energy balance in fat tissue.
Arrowhead Pharmaceuticals is preparing two RNAi-based drugs for obesity and metabolic diseases, aiming to start clinical trials early next year.